NCT05201781 2026-03-17
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
Phase 4 Recruiting
Clinical Trials
18 trialsNCT07474961 2026-03-16
BLOOD-dose
Rigshospitalet, Denmark
Phase 4 Not yet recruiting
NCT07426484 2026-02-23
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Dana-Farber Cancer Institute
Phase 4 Not yet recruiting
NCT07101445 2026-02-10
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Emory University
Phase 4 Recruiting
NCT06057402 2026-01-27
MagnetisMM15
Pfizer
Phase 4 Recruiting
NCT07334535 2026-01-13
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT07094048 2026-01-07
CHUQUL_HO001
CHU de Quebec-Universite Laval
Phase 4 Recruiting
NCT05722405 2026-01-05
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4 Recruiting
NCT04952766 2025-12-23
EREVA
Centre Hospitalier Régional d'Orléans
Phase 4 Completed
NCT06251076 2025-12-10
Plan Development for Giving Teclistamab in the Outpatient Setting
University Health Network, Toronto
Phase 4 Recruiting
NCT03829371 2025-12-03
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
University of Turin, Italy
Phase 4 Active not recruiting
NCT07025005 2025-11-04
VRd MM Fibrate
Tanta University
Phase 4 Recruiting
NCT07191379 2025-09-24
SCILLA
Odense University Hospital
Phase 4 Not yet recruiting
NCT07154537 2025-09-04
Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM)
National Taiwan University Hospital
Phase 4 Active not recruiting
NCT05160922 2025-09-03
Crizotinib Continuation Clinical Study
Pfizer
Phase 4 Active not recruiting
NCT03934684 2025-08-06
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma
Amgen
Phase 4 Completed
NCT06409702 2025-06-12
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
The First Affiliated Hospital of Soochow University
Phase 4 Recruiting
NCT05555329 2025-04-22
POMAlternative
Amsterdam UMC, location VUmc
Phase 4 Completed